New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT05173142

Completed Disease control Sponsor: Hutchison Medipharma Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drug shrinks tumors, especially in cancers with certain FGFR gene changes. The trial is complete, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HMPL-453 tartrate (oral drug) given alone or with chemotherapy (gemcitabine, cisplatin, docetaxel) or toripalimab (immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors with specific genetic changes.
What could go wrong: This is an early-phase trial (phase 1/2) with a small number of participants, so results may not lead to a proven therapy. Side effects from the drug combinations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Locations

Chinese PLA General Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.